eFFECTOR Therapeutics (EFTR) Stock Overview

A biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. More details

EFTR fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($940)

Latest financial reports are more than a year old

Shares are highly illiquid

EFTR Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

eFFECTOR Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for eFFECTOR Therapeutics
Historical stock prices
Current Share Price	US$0.0002
52 Week High	US$0.02
52 Week Low	US$0.0002
Beta	0
1 Month Change	-60.00%
3 Month Change	0%
1 Year Change	-33.33%
3 Year Change	-99.90%
5 Year Change	-99.90%
Change since IPO	-99.90%

Recent updates

Seeking Alpha • Sep 14

eFFECTOR doses first patient in second cohort of phase 1b trial of potential COVID drug

eFFECTOR Therapeutics (NASDAQ:EFTR) on Wednesday said it had dosed the first patient in the second cohort of its phase 1b clinical trial of its investigational cancer therapy zotatifin for the potential treatment of COVID-19. The early-stage trial is assessing the safety and antiviral activity of a single dose of zotatifin in patients with mild to moderate COVID, and is being conducted in collaboration with the University of California, San Francisco, EFTR said in a statement. The trial is being conducted using a $5M cooperative agreement sponsored by the government-led Defense Advanced Research Projects Agency. The dosing of the first patient in the second cohort follows a positive recommendation of an independent data safety board which reviewed data from the first dose cohort, EFTR said. EFTR stock marginally higher in morning trading.

Seeking Alpha • Aug 09

eFFECTOR Therapeutics GAAP EPS of -$0.17

eFFECTOR Therapeutics press release (NASDAQ:EFTR): Q2 GAAP EPS of -$0.17. Grant Revenue of $2.01M (+191.3% Y/Y). The company had cash and cash equivalents, and short-term investments totaling $41.0 million as of June 30, 2022, compared to $45.7 million in cash and cash equivalents as of March 31, 2022

Seeking Alpha • Sep 12

eFFECTOR: Developing New Class Of Cancer Therapies

eFFECTOR Therapeutics is pioneering the development of a new class of oncology drugs known as STRIs. The STRI therapy is also being evaluated for COVID-19 at UCSF under a DARPA grant. The company’s stock commenced trading on Nasdaq on 8/26/2021 after merger with SPAC Locust Walk Acquisition Corp. (LWAC).

Shareholder Returns

	EFTR	US Biotechs	US Market
7D	0%	-1.9%	-4.1%
1Y	-33.3%	23.6%	20.6%

Return vs Industry: EFTR underperformed the US Biotechs industry which returned 25% over the past year.

Return vs Market: EFTR underperformed the US Market which returned 22.3% over the past year.

Price Volatility

Is EFTR's price volatile compared to industry and market?
EFTR volatility
EFTR Average Weekly Movement	n/a
Biotechs Industry Average Movement	10.6%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.1%

Stable Share Price: EFTR's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine EFTR's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2012	n/a	n/a	effector.com

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company’s lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. It also develops Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer.

eFFECTOR Therapeutics, Inc. Fundamentals Summary

How do eFFECTOR Therapeutics's earnings and revenue compare to its market cap?
EFTR fundamental statistics
Market cap	US$940.00
Earnings (TTM)	-US$34.63m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is EFTR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EFTR income statement (TTM)
Revenue	US$0
Cost of Revenue	US$21.62m
Gross Profit	-US$21.62m
Other Expenses	US$13.02m
Earnings	-US$34.63m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did EFTR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/11 11:10
End of Day Share Price	2026/06/08 00:00
Earnings	2024/03/31
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

eFFECTOR Therapeutics, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Louise Chen	Cantor Fitzgerald & Co.
Robert Burns	H.C. Wainwright & Co.
Mara Goldstein	Mizuho Securities USA LLC

eFFECTOR Therapeutics (EFTR) Stock Overview

Risk Analysis

eFFECTOR Therapeutics, Inc. Competitors

Vincerx Pharma

Onconetix

Synairgen

AmeriCann

Price History & Performance

Recent News & Updates

eFFECTOR Therapeutics Files Form 15

eFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from NASDAQ Composite Index

eFFECTOR Therapeutics Provides Non-Compliance Update

eFFECTOR Therapeutics Plans to Voluntarily Request a Delisting of its Securities and Expects its Securities to be Delisted in the Near Term

eFFECTOR Therapeutics, Inc. Receives Written Notice from Nasdaq Regarding Minimum Value of Listed Securities

New major risk - Revenue and earnings growth

Recent updates

eFFECTOR Therapeutics Files Form 15

eFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from NASDAQ Composite Index

eFFECTOR Therapeutics Provides Non-Compliance Update

eFFECTOR Therapeutics Plans to Voluntarily Request a Delisting of its Securities and Expects its Securities to be Delisted in the Near Term

eFFECTOR Therapeutics, Inc. Receives Written Notice from Nasdaq Regarding Minimum Value of Listed Securities

New major risk - Revenue and earnings growth

eFFECTOR Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

eFFECTOR Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

New major risk - Market cap size

New major risk - Share price stability

eFFECTOR Therapeutics, Inc. Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer

Price target decreased by 92% to US$22.50

New major risk - Share price stability

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $15.000003 million.

Price target increased by 90% to US$275

eFFECTOR Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $15.000003 million.

eFFECTOR Therapeutics, Inc. Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Er+ Metastatic Breast Cancer Patients

eFFECTOR Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of Er+/Her2- Advanced Metastatic Breast Cancer

New major risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.13 loss per share (vs US$0.23 loss in 3Q 2022)

Effector Therapeutics, Inc. Announces Initiation of Dosing in an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Relapsed/Refractory Acute Myeloid Leukemia (Aml)

eFFECTOR Therapeutics, Inc. Appoints Caroline Loewy to its Board of Directors

Price target decreased by 11% to US$6.58

eFFECTOR Therapeutics Receives Non-Compliance Notice from Nasdaq Stock Market Regarding Non-Compliance with Nasdaq's Minimum Bid Price Requirement

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $8.733186 million.

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.49325 million.

Price target increased by 17% to US$7.38

eFFECTOR Therapeutics Receives Non-Compliance Notice from Nasdaq

eFFECTOR Therapeutics, Inc., Annual General Meeting, Jun 22, 2023

Price target increased by 16% to US$6.33

eFFECTOR Therapeutics, Inc. Provides Positive Clinical Data Update for Zotatifin and General Corporate Update

Price target decreased to US$8.60

Price target increased to US$10.75

High number of new directors

eFFECTOR doses first patient in second cohort of phase 1b trial of potential COVID drug

Consensus forecasts updated

Price target decreased to US$10.68

eFFECTOR Therapeutics GAAP EPS of -$0.17

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Consensus forecasts updated

Investor sentiment deteriorated over the past week

High number of new directors

Consensus forecasts updated

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Independent Director recently sold US$475k worth of stock

Independent Director recently sold US$407k worth of stock

Independent Director recently sold US$222k worth of stock

Independent Director recently sold US$917k worth of stock

Third quarter 2021 earnings released: EPS US$0.53

eFFECTOR: Developing New Class Of Cancer Therapies

Shareholder Returns

Price Volatility

About the Company

eFFECTOR Therapeutics, Inc. Fundamentals Summary

Earnings & Revenue

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources